Apoptosis in sepsis: a new target for therapeutic exploration
C Oberholzer, A Oberholzer, M Clare-Salzler… - The FASEB …, 2001 - Wiley Online Library
C Oberholzer, A Oberholzer, M Clare-Salzler, LL Moldawer
The FASEB Journal, 2001•Wiley Online LibraryThe treatment of sepsis and septic shock remains a clinical conundrum, and recent
prospective trials with biological response modifiers aimed at the inflammatory response
have shown only modest clinical benefit. Recently, interest has shifted toward therapies
aimed at reversing the accompanying periods of immune suppression. Studies in
experimental animals and critically ill patients have demonstrated that increased apoptosis
of lymphoid organs and some parenchymal tissues contributes to this immune suppression …
prospective trials with biological response modifiers aimed at the inflammatory response
have shown only modest clinical benefit. Recently, interest has shifted toward therapies
aimed at reversing the accompanying periods of immune suppression. Studies in
experimental animals and critically ill patients have demonstrated that increased apoptosis
of lymphoid organs and some parenchymal tissues contributes to this immune suppression …
Abstract
The treatment of sepsis and septic shock remains a clinical conundrum, and recent prospective trials with biological response modifiers aimed at the inflammatory response have shown only modest clinical benefit. Recently, interest has shifted toward therapies aimed at reversing the accompanying periods of immune suppression. Studies in experimental animals and critically ill patients have demonstrated that increased apoptosis of lymphoid organs and some parenchymal tissues contributes to this immune suppression, anergy, and organ system dysfunction. During sepsis syndromes, lymphocyte apoptosis can be triggered by the absence of IL‐2 or by the release of glucocorticoids, granzymes, or the so‐called ‘death’ cytokines: tumor necrosis factor a or Fas ligand. Apoptosis proceeds via auto‐activation of cytosolic and/or mitochondrial caspases, which can be influenced by the pro‐ and anti‐apoptotic members of the Bcl‐2 family. In experimental animals, not only can treatment with inhibitors of apoptosis prevent lymphoid cell apoptosis;it may also improve outcome. Although clinical trials with anti‐apoptotic agents remain distant due in large part to technical difficulties associated with their administration and tissue targeting, inhibition of lymphocyte apoptosis represents an attractive therapeutic target for the septic patient.—Oberholzer, C., Oberholzer, A., Clare‐Salzler, M., Moldawer, L. L. Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J. 15, 879–892 (2001)
![](/scholar/images/qa_favicons/wiley.com.png)
以上显示的是最相近的搜索结果。 查看全部搜索结果